JP2011510086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510086A5 JP2011510086A5 JP2010544393A JP2010544393A JP2011510086A5 JP 2011510086 A5 JP2011510086 A5 JP 2011510086A5 JP 2010544393 A JP2010544393 A JP 2010544393A JP 2010544393 A JP2010544393 A JP 2010544393A JP 2011510086 A5 JP2011510086 A5 JP 2011510086A5
- Authority
- JP
- Japan
- Prior art keywords
- imatinib
- patient
- pharmaceutically acceptable
- acceptable salt
- cmin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 48
- 229960002411 imatinib Drugs 0.000 claims description 48
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 9
- 230000002062 proliferating effect Effects 0.000 claims description 9
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 229960003685 imatinib mesylate Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2294508P | 2008-01-23 | 2008-01-23 | |
| US61/022,945 | 2008-01-23 | ||
| PCT/US2009/031510 WO2009094360A1 (en) | 2008-01-23 | 2009-01-21 | Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013261728A Division JP5881671B2 (ja) | 2008-01-23 | 2013-12-18 | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510086A JP2011510086A (ja) | 2011-03-31 |
| JP2011510086A5 true JP2011510086A5 (enExample) | 2013-05-09 |
| JP5936821B2 JP5936821B2 (ja) | 2016-06-22 |
Family
ID=40435094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544393A Expired - Fee Related JP5936821B2 (ja) | 2008-01-23 | 2009-01-21 | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 |
| JP2013261728A Expired - Fee Related JP5881671B2 (ja) | 2008-01-23 | 2013-12-18 | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013261728A Expired - Fee Related JP5881671B2 (ja) | 2008-01-23 | 2013-12-18 | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20100298338A1 (enExample) |
| EP (1) | EP2237783B1 (enExample) |
| JP (2) | JP5936821B2 (enExample) |
| KR (1) | KR101579993B1 (enExample) |
| CN (1) | CN101951910B (enExample) |
| AU (1) | AU2009206566A1 (enExample) |
| BR (1) | BRPI0906504A2 (enExample) |
| CA (1) | CA2712087A1 (enExample) |
| ES (1) | ES2526537T3 (enExample) |
| MX (1) | MX2010008103A (enExample) |
| PL (1) | PL2237783T3 (enExample) |
| PT (1) | PT2237783E (enExample) |
| RU (1) | RU2537223C2 (enExample) |
| WO (1) | WO2009094360A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2753391C1 (ru) * | 2020-09-29 | 2021-08-13 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0127922D0 (en) * | 2001-11-21 | 2002-01-16 | Novartis Ag | Organic compounds |
| SI1686997T1 (sl) * | 2003-11-18 | 2009-08-31 | Novartis Ag | Inhibitorji mutantne oblike KIT |
| US7329495B2 (en) * | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| DE602007012122D1 (de) * | 2006-09-22 | 2011-03-03 | Novartis Ag | Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib |
| AU2007323465B2 (en) | 2006-11-07 | 2011-08-04 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
-
2009
- 2009-01-21 ES ES09704256.8T patent/ES2526537T3/es active Active
- 2009-01-21 PL PL09704256T patent/PL2237783T3/pl unknown
- 2009-01-21 KR KR1020107018386A patent/KR101579993B1/ko not_active Expired - Fee Related
- 2009-01-21 JP JP2010544393A patent/JP5936821B2/ja not_active Expired - Fee Related
- 2009-01-21 BR BRPI0906504-0A patent/BRPI0906504A2/pt not_active IP Right Cessation
- 2009-01-21 US US12/863,627 patent/US20100298338A1/en not_active Abandoned
- 2009-01-21 MX MX2010008103A patent/MX2010008103A/es active IP Right Grant
- 2009-01-21 RU RU2010134916/15A patent/RU2537223C2/ru not_active IP Right Cessation
- 2009-01-21 CA CA2712087A patent/CA2712087A1/en not_active Abandoned
- 2009-01-21 WO PCT/US2009/031510 patent/WO2009094360A1/en not_active Ceased
- 2009-01-21 EP EP09704256.8A patent/EP2237783B1/en not_active Revoked
- 2009-01-21 AU AU2009206566A patent/AU2009206566A1/en not_active Abandoned
- 2009-01-21 PT PT97042568T patent/PT2237783E/pt unknown
- 2009-01-21 CN CN2009801027282A patent/CN101951910B/zh not_active Expired - Fee Related
-
2013
- 2013-12-18 JP JP2013261728A patent/JP5881671B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-27 US US14/924,207 patent/US20160045501A1/en not_active Abandoned
-
2016
- 2016-10-19 US US15/297,372 patent/US9763944B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220226295A1 (en) | Method of treatment with tradipitant | |
| JP2014517050A5 (enExample) | ||
| EA038531B1 (ru) | Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб | |
| JP2008509224A5 (enExample) | ||
| JP2019530711A5 (enExample) | ||
| JP2011510086A5 (enExample) | ||
| RU2010134916A (ru) | Способ оптимизации лечения иматинибом пролиферативных заболеваний, опосредованных рецептором тирозинкиназы kit | |
| CN100540004C (zh) | 经鼻给药的吡贝地尔药物组合物 | |
| CN115038446A (zh) | 马赛替尼治疗嗜酸性粒细胞性哮喘的用途 | |
| US8697702B2 (en) | Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate | |
| JP7250787B2 (ja) | 統合失調症の治療 | |
| WO2023127600A1 (ja) | Ｓｉｔｈ－１が関与する疾患の治療薬 | |
| CN1929841A (zh) | (+)－赤型－甲氟喹的药物组合物及其用途 | |
| HK1261581B (zh) | 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途 | |
| RU2016107968A (ru) | Фармацевтическая композиция для лечения функциональных психических расстройств | |
| HK1248552B (en) | Method of treatment with tradipitant | |
| HK1053792B (en) | Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis | |
| RU2009111604A (ru) | Дозы бифепрунокса для лечения шизофрении |